Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Kirk Look

<< Previous

Bullboard Posts

Next >>

Post by lonc17on Mar 30, 2024 8:43pm

190 Views

Post# 35961383

Kirk Look

Kirk Look is ONC's CFO. You would think he might be interested in following rules and regulations concerning publicly traded companies.

And yet, looking at SEDI, it appears he has little concern about violating rules around reporting of options. From my look at SEDI, Kirk Look stopped reporting issuance and expiration of his options in the year 2017.

That's a lot of fines he is accruing. I wonder if ONC pays his fines?

<< Previous

Bullboard Posts

Next >>

Mid-year update: Charting GameSquare’s sharp business growth